Lonza acquires biotech firm Synaffix

Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology

HMD supplied 1.75 billion syringes of the total 13.3 billion COVID 19 vaccines administered globally

HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date

Kristin Judge Joins Emmes as Chief Growth Officer

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement

USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause

Lilly allocates additional US $50 million to Social Impact Venture Capital portfolio

The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries

Gilead acquires XinThera to strengthen pipeline in oncology

Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors

Boehringer Ingelheim begins clinical development for fibrotic diseases

‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,

USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients